AN IN VIVO SHRNA-DRUG SCREEN TO IDENTIFY NOVEL TARGETED THERAPY COMBINATIONS FOR KRAS MUTANT CANCERS

$340,894FY2012Department of the ArmyDOD

The General Hospital Corporation

Investigators